| Document |
Document Title |
|
WO/2023/069770A1 |
Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as, for example, those caused by any viral family causing res...
|
|
WO/2023/067825A1 |
The present invention provides, inter alia: a method for producing an antibacterial composition, the method including producing a melanoidin by heating a reducing sugar selected from xylose or ribose, and an amino acid selected from phen...
|
|
WO/2023/065606A1 |
Disclosed is a new deuterated cyano compound as represented by formula I, or a pharmaceutically acceptable salt, an isomer or a prodrug thereof. Further disclosed are a method for preparing the deuterated compound, and a composition and ...
|
|
WO/2023/067273A1 |
The invention relates to the uses of cyclic amine monoamides for extracting uranium(VI) and/or plutonium(IV) from an acidic aqueous solution and also for completely or partially separating the uranium(VI) from the plutonium(IV) starting ...
|
|
WO/2023/068112A1 |
Provided are: a method for producing an antimicrobial composition, said method comprising heating a reducing sugar selected from xylose and ribose and an amino acid selected from phenylalanine and proline to produce a melanoidin and blen...
|
|
WO/2023/064493A1 |
This invention provides compounds for the inhibition of papain-like proteases (PLpros) for the inhibition of viruses, including compounds of formula (I"), and pharmaceutically acceptable salts thereof.
|
|
WO/2023/064370A1 |
Compounds and methods to treat or prevent CNS diseases, such as Alzheimer's disease and brain injury inflammation, are disclosed herein. The compounds are soluble epoxide hydrolase (sEH) inhibitors and have improved physical properties, ...
|
|
WO/2023/062627A1 |
Provided herein are compounds that inhibit the protein-protein interaction of serine acetyltransferase (SAT) with O-acetyl serine sulfhydrylase (OASS), and can therefore be used as herbicides.
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
|
WO/2023/057548A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.
|
|
WO/2023/051657A1 |
Provided are a compound as represented by formula I, and a racemate, an enantiomer, a diastereomer and a pharmaceutically acceptable salt thereof, and the use thereof in the prevention or treatment of related diseases caused by coronavir...
|
|
WO/2023/046768A1 |
The invention relates a method for producing amine N-oxide compounds of the formula (I) or (II), in which the R1 are selected from hydrocarbon groups with 4 to 26 C atoms and optionally at least one O or S atom; R2, R3, and R5 are select...
|
|
WO/2023/046885A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, ring A and the ring containing Q1 to Q5 have meanings as provided in the description. There is also provided medical uses of such ...
|
|
WO/2023/048337A1 |
The present specification relates to a compound represented by chemical formula 1, a salt, a stereoisomer, a solvent or a hydrate thereof, an antibacterial composition, a composition for inhibiting bacterial infections, a composition for...
|
|
WO/2023/047107A1 |
The present invention relates to compounds of formula (I) which may be used to treat a microbial infection or allergic reaction. In some embodiments, the microbial infection is leishmaniasis.
|
|
WO/2023/044333A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/044031A1 |
Many active pharmaceutical ingredients (API) are available in tablet form. Particles of the API should have a favorable compaction profile in order to be compressed into tablets, especially when the API is present in a large weight perce...
|
|
WO/2023/036217A1 |
The present invention relates to a class of acrylamide compounds and the use thereof, and specifically relates to a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/036945A1 |
The invention relates to a compound of formula (I) wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups.
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/036093A1 |
A class of ketoamide derivatives and an application thereof are disclosed. Specifically disclosed are a compound of formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/035571A1 |
Provided is a new synthesis method for an intermediate of esaxerenone. The method comprises: (1) reacting 2-(trifluoromethyl)phenylacetic acid as a raw material with ethyl chloroformate or isobutyl chloroformate in an inert solvent in th...
|
|
WO/2023/031335A1 |
The present invention relates to a process for the preparation of an optically pure (+) or (-) enantiomer of an iminium salt having the formula (I), aid process comprising the following steps: • a) a reduction step of an iminium salt h...
|
|
WO/2023/034510A1 |
Provided herein is a process for the preparation of 3,4-methylenedioxymethamphetamine, (R)-3,4-methylenedioxymethamphetamine and (S)-3,4-methylenedioxymethamphetamine.
|
|
WO/2023/029236A1 |
The present application provides a method for synthesizing a key intermediate II-a of upadacitinib. The asymmetric hydrogenation of unsaturated carboxylic acid I-a can be catalyzed by means of Ru(OAc)2-(R)-OSPD to synthesize chiral carbo...
|
|
WO/2023/030279A1 |
Provided are a 3, 3-difluoroallylic onium salt as represented by formula (C), and a preparation method of the substance. Cheap industrial raw materials are used to prepare the important fluorine-containing reagent, which can be used as a...
|
|
WO/2023/028077A1 |
The invention provides compounds of formulae I, II, Ila, and III, as described herein, and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.
|
|
WO/2023/021530A1 |
The present invention discloses an economical and improved, short process for synthesis of Molnupiravir from cytidine. The process of the present invention provides a novel intermediate N-Hydroxy Cytidine isobutyryl ester (13) which can ...
|
|
WO/2023/021363A1 |
The present invention relates to a novel compound of (S)-2-((Z)-((R)-4-propyldihydrofuran-2(3H)-ylidene) amino) butanamide and an improved, commercially viable process for preparation of Brivaracetam using (S)-2-((Z)-((R)-4-propyldihydro...
|
|
WO/2023/023469A1 |
Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.
|
|
WO/2023/020412A1 |
The present invention relates to a sulfonylurea compound represented by formula I, a preparation method therefore, and an application thereof. The compound of the present invention has soluble epoxide hydrolase (sEH) inhibitory activity ...
|
|
WO/2023/021895A1 |
Provided is an ionic liquid that can be used for semiconductor manufacturing and that has a low metal ion content.　This ionic liquid comprises cations and anions and contains, each by not more than 100 ppb, metal ions of 16 elements in...
|
|
WO/2023/018217A1 |
The present invention relates to a method for synthesizing bilirubin, and more specifically to a method for chemically synthesizing, for the first time, bilirubin and pegylated bilirubin, which are effectively used for medicines and the ...
|
|
WO/2023/018960A1 |
The invention provides novel improved methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
|
|
WO/2023/018215A1 |
The present invention relates to a method for synthesizing bilirubin. The present invention relates to a first method for chemically synthesizing bilirubin and PEGylated bilirubin, which are usefully used in a medicinal product or the li...
|
|
WO/2023/011938A1 |
The present invention relates to specific bismaleimide compounds, curable compositions comprising at least one of these bismaleimides and at least one specific polyimide. Furthermore, the present invention refers to a process for the man...
|
|
WO/2023/014793A1 |
The disclosure relates to synthetic methods for producing polyamides, for example pyrrole and imidazole containing polyamides of Formula (I) or (II), or a pharmaceutically acceptable salts thereof. These polyamides bind genes having expa...
|
|
WO/2023/014758A1 |
Provided are compounds of Formula (I), Formula (la), Formula (lb), and their use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or corona...
|
|
WO/2023/014768A1 |
Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables R1-10 are disclosed herein. The compounds are useful for treating central nervous system disorders, especi...
|
|
WO/2023/008644A1 |
The present invention relates to an organic compound and an organic light-emitting device comprising same, the organic compound being employed in an optical efficiency improvement layer, which is provided in an organic light-emitting dev...
|
|
WO/2023/004687A1 |
Provided by the present invention is an unnatural amino acid, which is a compound having a structure as shown in formula (I) or an enantiomer thereof. Further provided by the present invention is an application of the unnatural amino aci...
|
|
WO/2023/009521A1 |
This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates. Compound 1
|
|
WO/2023/006645A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, W, m and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/001088A1 |
The present invention discloses a preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride and (S) -3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride.
|
|
WO/2023/284611A1 |
ROS-responsive prodrugs and methods of making thereof are disclosed. These prodrugs can contain two captopril moieties and one cinnamaldehyde moiety that are linked by a thioacetal linking moiety; upon cleavage of the thioacetal linking ...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/285072A1 |
The present invention relates to compound of formula (I), a diastereomer, enantiomer, crystal or co-crystal thereof, or a pharmaceutically acceptable salt, or mixture thereof. The present invention also relates to pharmaceutical composit...
|
|
WO/2023/287938A1 |
The present disclosure encompasses solid state forms of Amcenestrant, in embodiments crystalline polymorphs of Amcenestrant, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/280155A1 |
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated...
|
